Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne-Els van de Logt

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Kidney360|April 4, 2022
Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: CONAnne-Els van de Logt, Jack F Wetzels
Kidney International Reports|September 22, 2025
Reassessing Rituximab in Membranous Nephropathy: Efficacy, Limitations, and the Path AheadAnne-Els van de Logt, Jack F M Wetzels
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 10, 2024
Treatment of membranous nephropathy: a novel approach?Anne-Els van de Logt, Jack F M Wetzels
Kidney International Reports|October 27, 2025
Sensitivity of Enzyme-Linked Immunosorbent Assay in Monitoring Treatment Response in Phospholipase A2 Receptor -Associated Membranous NephropathyCoralien Vink, Ruben Visch, Jack Wetzels, et al.
Kidney International Reports|June 15, 2022
COVID-19 Vaccination in Patients With Membranous NephropathyRuben Visch, Jack Wetzels, Coralien Vink, et al.
Kidney International|September 24, 2018
The authors replyAnne-Els van de Logt, Karine Dahan, Pierre Ronco, et al.
Expert Review of Clinical Pharmacology|August 19, 2016
Pharmacological treatment of primary membranous nephropathy in 2016Anne-Els van de Logt, Julia M Hofstra, Jack F Wetzels
Kidney International Reports|December 19, 2024
Combination Therapy With Rituximab and Low-Dose Cyclophosphamide and Prednisone in Membranous NephropathyCoralien H Vink, Jack F M Wetzels, Anne-Els van de Logt
Kidney International|October 16, 2019
The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discoveryAnne-Els van de Logt, Maryline Fresquet, Jack F Wetzels, et al.
Kidney International|May 30, 2015
Serum anti-PLA2R antibodies can be initially absent in idiopathic membranous nephropathy: seroconversion after prolonged follow-upAnne-Els van de Logt, Julia M Hofstra, Jack F M Wetzels
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Kidney360|April 4, 2022
Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: CONAnne-Els van de Logt, Jack F Wetzels
Kidney International Reports|September 22, 2025
Reassessing Rituximab in Membranous Nephropathy: Efficacy, Limitations, and the Path AheadAnne-Els van de Logt, Jack F M Wetzels
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 10, 2024
Treatment of membranous nephropathy: a novel approach?Anne-Els van de Logt, Jack F M Wetzels
Kidney International Reports|October 27, 2025
Sensitivity of Enzyme-Linked Immunosorbent Assay in Monitoring Treatment Response in Phospholipase A2 Receptor -Associated Membranous NephropathyCoralien Vink, Ruben Visch, Jack Wetzels, et al.
Kidney International Reports|June 15, 2022
COVID-19 Vaccination in Patients With Membranous NephropathyRuben Visch, Jack Wetzels, Coralien Vink, et al.
Kidney International|September 24, 2018
The authors replyAnne-Els van de Logt, Karine Dahan, Pierre Ronco, et al.
Expert Review of Clinical Pharmacology|August 19, 2016
Pharmacological treatment of primary membranous nephropathy in 2016Anne-Els van de Logt, Julia M Hofstra, Jack F Wetzels
Kidney International Reports|December 19, 2024
Combination Therapy With Rituximab and Low-Dose Cyclophosphamide and Prednisone in Membranous NephropathyCoralien H Vink, Jack F M Wetzels, Anne-Els van de Logt
Kidney International|October 16, 2019
The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discoveryAnne-Els van de Logt, Maryline Fresquet, Jack F Wetzels, et al.
Kidney International|May 30, 2015
Serum anti-PLA2R antibodies can be initially absent in idiopathic membranous nephropathy: seroconversion after prolonged follow-upAnne-Els van de Logt, Julia M Hofstra, Jack F M Wetzels
Pageof 4